Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584660 · ClinicalTrials.gov registry record · Phase 4
A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
A Phase 4 study, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- Phase 4
- Development phase
- 114
- Enrollment target
NCT02584660 is a Phase 4 study that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 114 participants.
The verdict
NCT02584660, a Phase 4 study, has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 114 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate that low risk Pulmonary Embolism (PE) participants who are discharged from the Emergency Department (ED) to the home environment and treated with rivaroxaban as outpatients have fewer total days in the hospital for bleeding and/or venous thromboembolism (VTE) events through Day 30 compared to participants who are treated with initial hospitalization and standard-of-care.
Interventions
- DRUG Rivaroxaban
- DRUG Standard-of-care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2015-10-15 |
| Est. Completion | 2017-03-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02584660
The ClinicalTrials.gov registry entry for NCT02584660 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rivaroxaban is the first listed.
NCT02584660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02584660 about?
NCT02584660 is a clinical study titled "A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department". The purpose of the study is to evaluate that low risk Pulmonary Embolism (PE) participants who are discharged from the Emergency Department (ED) to the home environment and treated with rivaroxaban as outpatients have fewer total days in the hospital for bleeding and/or venous thromboembolism (VTE) ...
What is the current status of trial NCT02584660?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 114 participants. The study started on 2015-10-15. Estimated completion is 2017-03-22.
What interventions are being tested in trial NCT02584660?
The interventions under investigation include: Rivaroxaban (DRUG), Standard-of-care (DRUG).
Who is sponsoring clinical trial NCT02584660?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.